{"id":"W3212509840","doi":"10.1182/blood-2021-149478","title":"A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; CD22; Calicheamicin; Interim analysis; Minimal residual disease; Surgery; Hematopoietic stem cell transplantation; Chemotherapy; Gastroenterology; Transplantation; Oncology; Bone marrow; Randomized controlled trial; Lymphoma; CD20","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002926448,0.002593745,0.002184136,0.0004780596,0.0007334607,0.001456168,0.001349785,0.001688029,0.0123269],"category_scores_gemma":[0.002380313,0.0008922925,0.00140367,0.0006081652,0.001053123,0.0008830433,0.000536353,0.00414585,0.001820907],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001890337,"about_ca_system_score_gemma":0.004111058,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002260462,"about_ca_topic_score_gemma":0.005943542,"domain_scores_codex":[0.9990684,0.0005400865,0.00003646549,0.0001166827,0.00008642967,0.0001518955],"domain_scores_gemma":[0.9985577,0.0002572816,0.0004138894,0.0001004999,0.0001048321,0.0005656798],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9400751,0.01238407,0.002107746,0.001076523,0.001007131,0.0001730649,0.0001048837,0.001034058,0.006031638,0.0005207705,0.01315185,0.02233318],"study_design_scores_gemma":[0.9591294,0.03439323,0.002168987,0.00005024613,0.0001993664,0.00008387026,0.00001681366,0.0004229742,0.0004634217,0.0002536803,0.00280277,0.00001530397],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8908865,0.006464925,0.002252654,0.003192808,0.001131693,0.0694975,0.01571971,0.0007764371,0.01007783],"genre_scores_gemma":[0.8515567,0.005177893,0.008796467,0.005923555,0.0007531547,0.1026413,0.01190685,0.0002493339,0.01299483],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0123269,"threshold_uncertainty_score":0.04123759,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01948813220071422,"score_gpt":0.3483837757388616,"score_spread":0.3288956435381474,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}